Biotechnology Healthcare - July/August 2008 - (Page 56)

CALL FOR PAPERS BIOTECHNOLOGY HEALTHCARE publishes peer-reviewed articles for decision makers at third-party payer organizations; employers and other healthcare purchasers; and those who have a stake in the clinical, economic, benefit design, and health policy implications of biologic medicine. Through balanced coverage from a variety of perspectives, we strive to educate readers in a way that enables them to make informed value judgments and decisions about biopharmaceuticals and molecular diagnostics. We publish feature articles on such topics as biologic therapies and diagnostic capabilities; clinical outcomes and cost effectiveness; benefit design and cost-management strategies; effects of treatment on employee productivity; and issues related to patient access and affordability. We also welcome essays, review articles, and original research from qualified experts in biotechnology, specialty pharmacy, managed care, and employee benefits whose experience can be instructive for payers, purchasers, and policymakers. David Nash, MD, MBA, the Dr. Raymond C. and Doris N. Grandon Professor and chairman of the Department of Health Policy at Jefferson Medical College of Thomas Jefferson University, leads BIOTECHNOLOGY HEALTHCARE’S editorial advisory board. Nash has enrolled a distinguished panel to review manuscripts for publication. BIOTECHNOLOGY HEALTHCARE is indexed in CINAHL and International Pharmaceutical Abstracts. All references in text must be placed within parentheses, using the first author’s last name and the year of publication, e.g., (Smith 2008). At the end of the paper, include a list of citations (alphabetical by first author), and format each citation in accordance with the American Medical Association Manual of Style (10th edition). Authors are responsible for accuracy and completeness of references. SUBMISSIONS An electronic version of the manuscript should be sent via e-mail to Michael D. Dalzell, editor, BIOTECHNOLOGY HEALTHCARE, at «mdalzell@medimedia.com». Most wordprocessing programs are acceptable, though Microsoft Word is preferred. Please include a cover letter with your submission. The cover letter should include: • Manuscript title and a brief explanation of its importance to our readers. • A statement affirming that this work is not under consideration for publication by other media and that it has not been published elsewhere. • A list of all authors. Authorship is defined by Section 2 of the Uniform Requirements. For each author, include full name, advanced degrees, pertinent affiliations, mailing addresses, telephone and fax numbers, and e-mail addresses. • Designation of a corresponding author. • Consent to transfer copyright to BIOTECHNOLOGY HEALTHCARE on publication. A disclosure statement identifying any potential financial conflicts of interest, and acknowledging the source(s) of financial support also should be included with your submission. Download the BIOTECHNOLOGY HEALTHCARE conflictof-interest form at «www.biotechnologyhealthcare.com». INSTRUCTIONS FOR AUTHORS BIOTECHNOLOGY HEALTHCARE accepts manuscripts that have not been published elsewhere and are not under consideration for publication by other print or electronic media. Authors are required to disclose direct or indirect conflicts of interest or appearances thereof. Should BIOTECHNOLOGY HEALTHCARE publish a submission, authors agree to transfer the copyright to BIOTECHNOLOGY HEALTHCARE. To streamline the review process, we ask authors of essays, review articles, original research, and other nonfeature articles to adhere to these guidelines: Unless otherwise specified herein, manuscripts should conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, developed by the International Committee of Medical Journal Editors and available at «http://www.icmje.org». Please review Section 4 of the Uniform Requirements before submitting work. Manuscripts should be no more than 4,000 words including abstract, references, and tables but not including figures or illustrations. Please include an abstract summarizing key points and including key terms. Include written permission from publishers to reproduce previously published illustrations and tables. Use generic drug names when identifying pharmaceutical products, unless brand names are important. On first reference, identify brands in parentheses after the generic name. REVIEW PROCESS BIOTECHNOLOGY HEALTHCARE will review the manuscript for appropriateness and will notify the corresponding author whether it is under consideration for publication. Articles under such consideration will be sent to expert peer reviewers selected by the editor. Manuscripts recommended by peer reviewers for publication are edited inhouse. If the reviewers recommend extensive revisions, authors may be asked to revise their work and then to resubmit the article. BIOTECHNOLOGY HEALTHCARE reserves the right to edit text for clarity, style, and length. Final drafts will be sent to authors for review before publication. Articles published in BIOTECHNOLOGY HEALTHCARE become the property of BioCommunications LLC and may not be reproduced without permission of the publisher. 56 BIOTECHNOLOGY HEALTHCARE · JULY/AUGUST 2008 http://www.biotechnologyhealthcare.com http://www.icmje.org

Table of Contents Feed for the Digital Edition of Biotechnology Healthcare - July/August 2008

Biotechnology Healthcare - July/August 2008 Openers Contents Editorial/David B. Nash, MD, MBA Drug Track Health Plan Confidential Rheumatoid Arthritis A Decade of Trial, Error, False Starts, and Hope What Path Will Comparative Effectiveness Research Take? RA Therapies in Development: A New Generation of Relief Assessing the Full Impact of RA on Employers and Payers Stem Cells: Health Insurance You Can Bank On Specialty Pharmacy Employer to Employer Personalized Medicine Trends Clinical Briefs

Biotechnology Healthcare - July/August 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.